View Post

Mature Data Drive New Insights With Novel Agents in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic. The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates (ADCs), and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic, explained Lisa A. Carey, MD, FASCO. …

View Post

A pill for breast cancer? There’s one for early-stage patients with aggressive cases — and it works

In In The News by Barbara Jacoby

By: Peter Loftus, Wall Street Journal From: geneticliteracyproject.org A drug sold by AstraZeneca and Merck & Co. reduced the recurrence of breast cancer in women with an early but aggressive form of the disease, a long-running international study found. The finding, which on [June 3] was published online by the New England Journal of Medicine and released at a major …

View Post

Triple-Negative Breast Cancer Treatments Continue to Evolve

In In The News by Barbara Jacoby

By: HAYLEY VIRGIL From: oncnursingnews.com Beyond single-agent chemotherapy, few effective treatment options are available for metastatic triple-negative breast cancer (TNBC), according to Candace Mainor, MD, but several approaches comprised of immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors are shifting standards of care and eliciting impressive response rates in heavily pretreated patients. “There are some exciting new therapies for the treatment …

View Post

Optimal Sequencing Remains a Hurdle in Ovarian Cancer Treatment

In Clinical Studies News by Barbara Jacoby

By: Brittany Lovely From: onclive.com The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians. Bevacizumab (Avastin) continues to hold the most utility in this disease setting, but the addition of PARP inhibitors, and immunotherapy raises the question of how to best deliver efficient regimens to patients. …

View Post

Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond

In Clinical Studies News by Barbara Jacoby

By: Ellie Leick From: onclive.com The use of PARP inhibitors has greatly expanded in the treatment of patients with BRCA-mutated breast cancer in recent years, according to Melinda L. Telli, MD, and research efforts are now examining these agents in novel combinations and beyond the BRCA setting. In January 2018, olaparib (Lynparza) joined the treatment arsenal for use as a …

View Post

Could even more cancer patients benefit from PARP inhibitors?

In In The News by Barbara Jacoby

By: Arlene Weintraub From: fiercebiotech.com PARP inhibitors like AstraZeneca’s Lynparza and Tesaro’s Zejula have revolutionized the treatment of ovarian cancers with BRCA mutations and are starting to take off in breast cancer treatment too. But the way that these drugs work could make them applicable to many more cancer types, some oncology researchers believe. The latest evidence of that comes from Yale University, …

View Post

AstraZeneca Cancer Drug, Companion Test Approved

In In The News by Barbara Jacoby

By: Linda A. Johnson From: centredaily.com U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC. The drug is for women whose ovarian cancer is associated with certain defective genes and whose cancer persists after multiple treatments. Women with mutated BRCA genes have a …